FDA Approves First Daily Cholesterol Pill That Can Cut LDL by Nearly 60%

For decades, statins have been the most common type of medication that doctors and patients use to combat high cholesterol. While highly effective for many patients, statins don't always lower cholesterol enough on their own. In recent years, injectable PCSK9 inhibitors have offered another powerful option, but the need for regular injections has limited their use for some patients.

In what might prove to be a turning point for cholesterol treatment, the FDA has approved a medication called Lipfendra (enlicitide). Lipfendra is the first once-daily oral PCSK9 inhibitor. The new medication gives patients access to the cholesterol-lowering power of this class of drugs in pill form, potentially making advanced treatment more convenient and accessible. In clinical trials, Lipfendra reduced LDL cholesterol, or "bad" cholesterol, by approximately 56% to 60% when used alongside statin therapy.

A New Option for Patients Who Need More Than Statins

It is widely expected that statins will remain the first line of defense against LDL cholesterol. They are widely available, have decades of data, and have proven effective for millions of patients over the years. However, some patients, including those with inherited forms of high cholesterol or established cardiovascular disease, continue to have elevated LDL levels despite taking the highest tolerated doses.

The FDA approved Lipfendra as an add-on treatment for adults with hypercholesterolemia, including certain inherited forms of the condition. It’s not currently designed to replace statins. Instead, it is intended to help patients who need additional cholesterol reduction to lower their cardiovascular risk.

How PCSK9 Inhibitors Lower Cholesterol

Lipfendra belongs to a class of drugs known as PCSK9 inhibitors. While not as widely known as statins, this category of cholesterol medication has been an important part of improving heart health for years. However, Lipfendra is the first example of it being a daily oral tablet. Until now, every FDA-approved PCSK9 inhibitor required injections every few weeks or months.

PCSK9 is a protein that affects the liver's ability to remove LDL cholesterol from the bloodstream. By blocking this protein, the medication allows the liver to clear more LDL from the blood, resulting in substantially lower cholesterol levels.

Clinical Trials Showed Significant LDL Reductions

Before the FDA approves a medication, it must go through rigorous testing and clinical trials. Lipfendra’s approval was based on multiple Phase 3 clinical trials involving adults whose cholesterol remained above recommended levels despite ongoing treatment.

When used in conjunction with statins, Lipfendra consistently lowered LDL cholesterol by between 56% and 60%. According to physicians, including some who were not directly involved with the study, this figure is substantially greater than what patients experience when taking statins alone.

Fox News medical contributor Dr. Marc Siegel highlighted the significance of the findings, saying, "This is around double the impact of statins." He also explained that while cholesterol plays an important biological role, elevated LDL can become harmful over time because it contributes to plaque buildup inside arteries.

Convenience Could Improve Long-Term Treatment

Experts agree that Lipfendra’s ease of use may be the most noticeable benefit that the new drug provides. Although injectable PCSK9 inhibitors have proven highly effective, some patients hesitate to begin injectable therapies or have difficulty remaining consistent with treatment schedules. A daily pill may encourage greater adherence, allowing more patients to benefit from intensive cholesterol-lowering.

According to reports, Lipfendra will carry a list price of about $315 per month, though actual out-of-pocket costs will depend on insurance coverage and manufacturer assistance programs. Merck expects the medication to become available within weeks of FDA approval.

Researchers Still Need Long-Term Outcome Data

The early findings are certainly impressive, but researchers still need long-term data to fully understand the potential benefits of Lipfendra on heart health. Researchers are still studying whether Lipfendra reduces the risk of heart attacks, strokes, and cardiovascular death over the long term.

Lowering LDL cholesterol has long been associated with decreasing the likelihood of a cardiac event. However, regulators and physicians also look for direct evidence that new medications improve patient outcomes. Merck has an ongoing cardiovascular outcomes trial that is expected to provide additional data in the coming years. Until that data is gathered and released, experts will continue to view Lipfendra as an important new tool for lowering cholesterol in patients who require more aggressive treatment.

The FDA's approval of Lipfendra marks an important advancement in cholesterol treatment by bringing the first oral PCSK9 inhibitor to patients who need additional LDL reduction beyond what statins can provide. With clinical trials showing cholesterol reductions approaching 60%, the medication offers a promising new option for people at increased cardiovascular risk.

Looking for stories that inform and engage? From breaking headlines to fresh perspectives, WaveNewsToday has more to explore.